BridgeBio Pharma BBIO Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

PfizerPFE

——

Tenet HealthcareTHC

——

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$12.98B+119%

Enterprise value$15.36B+178%

P/S22.4×-24.1×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BridgeBio Pharma's debt instrument, unamortized discount (premium) and debt issuance costs, net?: BridgeBio Pharma (BBIO) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $53.43M in Q1 2026.